Author
Bradford, EricJacobson, Sean
Varasteh, Jason
Comellas, Alejandro P.
Woodruff, Prescott
O’Neal, Wanda
DeMeo, Dawn L.
Li, Xingnan
Kim, Victor
Cho, Michael
Castaldi, Peter J.
Hersh, Craig
Silverman, Edwin K.
Crapo, James D.
Kechris, Katerina
Bowler, Russell P.

Affiliation
Univ Arizona, Coll Med, Dept MedIssue Date
2017-10-24
Metadata
Show full item recordPublisher
BIOMED CENTRAL LTDCitation
The value of blood cytokines and chemokines in assessing COPD 2017, 18 (1) Respiratory ResearchJournal
Respiratory ResearchRights
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background: Blood biomarkers are increasingly used to stratify high risk chronic obstructive pulmonary disease (COPD) patients; however, there are fewer studies that have investigated multiple biomarkers and replicated in multiple large well-characterized cohorts of susceptible current and former smokers. Methods: We used two MSD multiplex panels to measure 9 cytokines and chemokines in 2123 subjects from COPDGene and 1117 subjects from SPIROMICS. These biomarkers included: interleukin (IL)-2, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, eotaxin/CCL-11, eotaxin-3/CCL-26, and thymus and activation-regulated chemokine (TARC)/CCL-17. Regression models adjusted for clinical covariates were used to determine which biomarkers were associated with the following COPD phenotypes: airflow obstruction (forced expiratory flow at 1 s (FEV1%) and FEV1/forced vital capacity (FEV1/FVC), chronic bronchitis, COPD exacerbations, and emphysema. Biomarker-genotype associations were assessed by genome-wide association of single nucleotide polymorphisms (SNPs). Results: Eotaxin and IL-6 were strongly associated with airflow obstruction and accounted for 3-5% of the measurement variance on top of clinical variables. IL-6 was associated with progressive airflow obstruction over 5 years and both IL-6 and IL-8 were associated with progressive emphysema over 5 years. None of the biomarkers were consistently associated with chronic bronchitis or COPD exacerbations. We identified one novel SNP (rs9302690 SNP) that was associated with CCL17 plasma measurements. Conclusion: When assessing smoking related pulmonary disease, biomarkers of inflammation such as IL-2, IL-6, IL-8, and eotaxin may add additional modest predictive value on top of clinical variables alone.Note
Open Access Journal.ISSN
1465-993XPubMed ID
29065892Version
Final published versionSponsors
National Heart, Lung, and Blood Institute [R01 HL129937, R01 HL089897, R01 HL089856]; COPD Foundation; NIH/NHLBI [HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C]ae974a485f413a2113503eed53cd6c53
10.1186/s12931-017-0662-2
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.
Related articles
- Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.
- Authors: Keene JD, Jacobson S, Kechris K, Kinney GL, Foreman MG, Doerschuk CM, Make BJ, Curtis JL, Rennard SI, Barr RG, Bleecker ER, Kanner RE, Kleerup EC, Hansel NN, Woodruff PG, Han MK, Paine R 3rd, Martinez FJ, Bowler RP, O'Neal WK, COPDGene and SPIROMICS Investigators ‡
- Issue date: 2017 Feb 15
- Thymus and activation-regulated chemokine (TARC/CCL17) predicts decline of pulmonary function in patients with chronic obstructive pulmonary disease.
- Authors: Machida H, Inoue S, Shibata Y, Kimura T, Sato K, Abe K, Murano H, Yang S, Nakano H, Sato M, Nemoto T, Sato C, Nishiwaki M, Yamauchi K, Igarashi A, Tokairin Y, Watanabe M
- Issue date: 2021 Jan
- Inverse association of plasma IL-13 and inflammatory chemokines with lung function impairment in stable COPD: a cross-sectional cohort study.
- Authors: Lee JS, Rosengart MR, Kondragunta V, Zhang Y, McMurray J, Branch RA, Choi AM, Sciurba FC
- Issue date: 2007 Sep 14
- Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD.
- Authors: Sun W, Kechris K, Jacobson S, Drummond MB, Hawkins GA, Yang J, Chen TH, Quibrera PM, Anderson W, Barr RG, Basta PV, Bleecker ER, Beaty T, Casaburi R, Castaldi P, Cho MH, Comellas A, Crapo JD, Criner G, Demeo D, Christenson SA, Couper DJ, Curtis JL, Doerschuk CM, Freeman CM, Gouskova NA, Han MK, Hanania NA, Hansel NN, Hersh CP, Hoffman EA, Kaner RJ, Kanner RE, Kleerup EC, Lutz S, Martinez FJ, Meyers DA, Peters SP, Regan EA, Rennard SI, Scholand MB, Silverman EK, Woodruff PG, O'Neal WK, Bowler RP, SPIROMICS Research Group, COPDGene Investigators
- Issue date: 2016 Aug
- Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.
- Authors: Pratte KA, Curtis JL, Kechris K, Couper D, Cho MH, Silverman EK, DeMeo DL, Sciurba FC, Zhang Y, Ortega VE, O'Neal WK, Gillenwater LA, Lynch DA, Hoffman EA, Newell JD Jr, Comellas AP, Castaldi PJ, Miller BE, Pouwels SD, Hacken NHTT, Bischoff R, Klont F, Woodruff PG, Paine R, Barr RG, Hoidal J, Doerschuk CM, Charbonnier JP, Sung R, Locantore N, Yonchuk JG, Jacobson S, Tal-Singer R, Merrill D, Bowler RP
- Issue date: 2021 Apr 27